Results 161 to 170 of about 21,930 (203)
Some of the next articles are maybe not open access.
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis
Hormone and Metabolic Research, 2020Abstract3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation.
Helena Panteliou, Lima-Valassi +6 more
openaire +2 more sources
Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway
Current Molecular Pharmacology, 2017Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by pharmaceuticals, commonly referred to as statins, has proven to be an effective and efficient way in reducing cholesterol levels in patients. As a result of this intervention, mevalonate production, formed during cholesterol synthesis, is inhibited.
Alison L, Muller, Darren H, Freed
openaire +2 more sources
Both the mevalonate and the non-mevalonate pathways are involved in ginsenoside biosynthesis
Plant Cell Reports, 2013When one of them was inhibited, the two pathways could compensate with each other to guarantee normal growth. Moreover, the sterol biosynthesis inhibitor miconazole could enhance ginsenoside level.Ginsenosides, a kind of triterpenoid saponins derived from isopentenyl pyrophosphate (IPP), represent the main pharmacologically active constituents of ...
Shoujing, Zhao +5 more
openaire +2 more sources
Cardioprotection by Farnesol: Role of the Mevalonate Pathway
Cardiovascular Drugs and Therapy, 2013Farnesol is a key metabolite of the mevalonate pathway and known as an antioxidant. We examined whether farnesol treatment protects the ischemic heart.Male Wistar rats were treated orally with 0.2, 1, 5, and 50 mg/kg/day farnesol/vehicle for 12 days, respectively. On day 13, the effect of farnesol treatment on cardiac ischemic tolerance and biochemical
Szűcs, Gergő +8 more
openaire +3 more sources
Biochemistry of the non-mevalonate isoprenoid pathway
Cellular and Molecular Life Sciences, 2011The non-mevalonate pathway of isoprenoid (terpenoid) biosynthesis is essential in many eubacteria including the major human pathogen, Mycobacterium tuberculosis, in apicomplexan protozoa including the Plasmodium spp. causing malaria, and in the plastids of plants.
Tobias, Gräwert +4 more
openaire +2 more sources
Druggability of the enzymes of the non-mevalonate-pathway
Drug Discovery Today, 2013The non-mevalonate pathway constitutes a source of novel drug targets. This biosynthetic route is essential for pathogens but is absent in humans. Our systematic evaluation of the druggability of all enzymes provides a convenient way of selecting targets that should be most easily inhibited by small-molecule drugs.
Tiziana, Masini +2 more
openaire +2 more sources
Key Enzymes for the Mevalonate Pathway in the Cardiovascular System
Journal of Cardiovascular Pharmacology, 2021Abstract: Isoprenylation is an important post-transcriptional modification of small GTPases required for their activation and function. Isoprenoids, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate, are indispensable for isoprenylation by serving as donors of a prenyl moiety to small G proteins.
Chi, Zhang +4 more
openaire +2 more sources
Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design, 2012Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes.
A. Marcuzzi +5 more
openaire +3 more sources
Targeting the mevalonate pathway in multiple myeloma
Leukemia Research, 2010Multiple myeloma is an incurable plasma cell malignancy. Although novel agents have improved overall survival in the last decade, multidrug resistance eventually still occurs in all patients. New treatment strategies are therefore needed. Statins are HMG-CoA reductase inhibitors that are well known as treatment for hypercholesterolemia. In addition, in
openaire +2 more sources
A Biosynthetic Pathway to Isovaleryl‐CoA in Myxobacteria: The Involvement of the Mevalonate Pathway
ChemBioChem, 2005AbstractA biosynthetic shunt pathway branching from the mevalonate pathway and providing starter units for branched‐chain fatty acid and secondary metabolite biosynthesis has been identified in strains of the myxobacterium Stigmatella aurantiaca. This pathway is upregulated when the branched‐chain α‐keto acid dehydrogenase gene (bkd) is inactivated ...
Mahmud, T. +6 more
openaire +3 more sources